Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

Bone Marrow Transplantation volume 47, pages 483–487 (2012)Cite this article

Abstract

Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients with hematological malignancies. Unfortunately, 15–30% of patients fail to mobilize a sufficient number of HSCs for the transplant. Plerixafor is now used as a salvage mobilization regimen, with good success. We describe here a risk-based approach for the use of plerixafor, based on the circulating CD34+ cell count and the CD34+ cell dose collected after 4 days of G-CSF, that identifies potential poor HSC mobilizers upfront. A total of 159 patients underwent HSC collections using this approach. Of these, 55 (35%) were identified as high risk owing to low CD34+ cell number or low yield on day 1 of collection, and received plerixafor on the subsequent days of collection. Of the 159 patients, 151 (95%) were able to provide adequate collections with the first mobilization attempt in a median of 1.7 days using this approach. Of the eight who failed initial mobilization, 5 successfully underwent re-mobilization with plerixafor and G-CSF and 3 (1.9%) were mobilization failures. This approach helped to control the overall cost of HSC collections for our BMT program by decreasing the need for remobilization, reducing the number of collection days and avoiding the use of plerixafor in all patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E . Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655–3663.

    Article  PubMed  Google Scholar 

  2. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC et al. High-dose chemotherapy and autologous hematopoietic stem- cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851.

    Article  CAS  PubMed  Google Scholar 

  3. Wright DE, Cheshier SH, Wagers AJ, Randall TD, Christensen JL, Weissman IL . Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. Blood 2001; 97: 2278–2285.

    Article  CAS  PubMed  Google Scholar 

  4. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A et al. Mobilization of CD34+ cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–423.

    Article  PubMed  Google Scholar 

  5. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490–499.

    Article  CAS  PubMed  Google Scholar 

  6. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316.

    CAS  PubMed  Google Scholar 

  7. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N . AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmocol 2009; 75: 1240–1247.

    Article  CAS  Google Scholar 

  8. Lapidot T, Petit I . Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973–981.

    Article  CAS  PubMed  Google Scholar 

  9. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307–1318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  PubMed  Google Scholar 

  11. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  PubMed  Google Scholar 

  12. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  PubMed  Google Scholar 

  13. Demirer T, Ilhan O, Ayli M, Arat M, Dagli M, Ozcan M et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6: 384–389.

    Article  PubMed  Google Scholar 

  14. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK . Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64–69.

    Article  CAS  PubMed  Google Scholar 

  15. Tornatta J, Maciejewski JJ, Nathan S, McLeod BC, Rhoades D, Palaparthy S . Efficacy of administration of plerixafor (Mozobil®) at 5:00 PM for stem cell mobilization (SCM) in patients receiving autologous stem cell transplant. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3218.

    Google Scholar 

  16. Burger JA, Peled A . CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43–52 .

    Article  CAS  PubMed  Google Scholar 

  17. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells – definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490–499.

    Article  CAS  PubMed  Google Scholar 

  18. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34 positive cell determination by flow cytometry. Hematotherapy 1996; 5: 213–226.

    Article  CAS  Google Scholar 

  19. Yang SH, Wang TF, Tsai HH, Lin TY, Wen SH, Chen SH . Preharvest hematopoietic progenitor cell counts predict CD34+ cell yields in granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell harvest in healthy donors. Transfusion 2010; 50: 1088–1095 .

    Article  PubMed  Google Scholar 

  20. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, Macpherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729–736.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Kathy Gaillard RN, Anne Hirner RN, Melissa Torry RN (Pheresis nursing staff) and Laure Dubois, Pharm D, Leigh Casey Pharm D and Clint Divine, for helping with the algorithm and the manuscript.

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, The University of Kansas Medical Center, Shawnee Mission Parkway, Westwood, KS, USA

    S Abhyankar, O Aljitawi, S Ganguly & J McGuirk

  2. Blood and Marrow Transplant Program, The University of Kansas Medical Hospital, Shawnee Mission Parkway, Westwood, KS, USA

    S DeJarnette & D Merkel

Authors
  1. S Abhyankar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S DeJarnette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Aljitawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Ganguly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Merkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J McGuirk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Abhyankar.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abhyankar, S., DeJarnette, S., Aljitawi, O. et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 47, 483–487 (2012). https://doi.org/10.1038/bmt.2011.133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.133

Keywords

This article is cited by

Search

Advanced search

Quick links